Waking up from some big blockbuster dreams, Pfizer scraps a $250M drug deal as data sour, safety fears rise
A little over 2 years after Pfizer paid Ionis $250 million cash to in-license rights to vupanorsen (AKCEA-ANGPTL3-LRx) — immediately vaulting the drug onto its list of top prospects — the pharma giant has decided to ax its ambitious late-stage work on the drug and hand it all back to Ionis, which has had more than its share of setbacks recently.
Pfizer had at one time been extremely bullish on this drug’s mid-stage data, grabbing exclusive worldwide rights, but researchers say they took a cold, hard look at the data from their Phase IIb and found the therapy wanting on efficacy as well as safety.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
